Trial Profile
Evaluation of immunological response following a revaccination with PPS23 boosted or not by PCV13 in splenectomised patients (SPLENEVAC-2)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms SPLENEVAC-2
- 10 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 14 Mar 2022 Planned End Date changed from 1 Feb 2024 to 1 Jun 2024.
- 14 Mar 2022 Planned primary completion date changed from 1 Feb 2023 to 1 Jun 2023.